Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...
A 1,563‑sample chromatin atlas reveals 16 epigenomic subgroups of AML, redefining disease classification, prognosis, and therapeutic vulnerabilities.
The 2026 primary schedule is listed below with the date of each state's primary races.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results